Targeting the CCL19/CCR7 complex, necessary for lymphocyte trafficking and also overexpressed in our AIH cohort, could represent a novel anti-inflammatory drug discovery approach [69]. This evidence concerns the gene CCR7 and autoimmune hepatitis.